ATE390915T1 - Sprühgetrocknete insulin-mikropartikel zur inhalation - Google Patents

Sprühgetrocknete insulin-mikropartikel zur inhalation

Info

Publication number
ATE390915T1
ATE390915T1 AT99928111T AT99928111T ATE390915T1 AT E390915 T1 ATE390915 T1 AT E390915T1 AT 99928111 T AT99928111 T AT 99928111T AT 99928111 T AT99928111 T AT 99928111T AT E390915 T1 ATE390915 T1 AT E390915T1
Authority
AT
Austria
Prior art keywords
inhalation
spray dried
dried insulin
insulin microparticles
microparticles
Prior art date
Application number
AT99928111T
Other languages
English (en)
Inventor
Stuart Robinson
Susan Smith
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of ATE390915T1 publication Critical patent/ATE390915T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99928111T 1998-06-30 1999-06-28 Sprühgetrocknete insulin-mikropartikel zur inhalation ATE390915T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9814172.4A GB9814172D0 (en) 1998-06-30 1998-06-30 Formulation for inhalation

Publications (1)

Publication Number Publication Date
ATE390915T1 true ATE390915T1 (de) 2008-04-15

Family

ID=10834700

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928111T ATE390915T1 (de) 1998-06-30 1999-06-28 Sprühgetrocknete insulin-mikropartikel zur inhalation

Country Status (14)

Country Link
EP (1) EP1091729B1 (de)
JP (1) JP2002519315A (de)
CN (1) CN1198582C (de)
AT (1) ATE390915T1 (de)
AU (1) AU752563B2 (de)
BR (1) BR9911697A (de)
CA (1) CA2336376C (de)
DE (1) DE69938452T2 (de)
DK (1) DK1091729T3 (de)
EA (1) EA200100088A1 (de)
ES (1) ES2303378T3 (de)
GB (1) GB9814172D0 (de)
IL (1) IL140306A0 (de)
WO (1) WO2000000176A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69121930T2 (de) * 1990-02-08 1997-04-03 Canon Kk Bildaufnahmevorrichtung
US6315983B1 (en) 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001254995A1 (en) * 2000-05-15 2001-11-26 Vectura Limited Method of manufacturing particles
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
EP1309312A2 (de) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhalierbare sprühgetrocknete pulver aus proteinen die bündel aus 4 helices ausbilden mit minimierter aggregation
EP1392262A1 (de) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Verabreichung von arzneimittel-estern durch inhalation
WO2002094242A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6737043B2 (en) 2001-05-24 2004-05-18 Alexza Molecula Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1458360B1 (de) 2001-12-19 2011-05-11 Novartis AG Pulmonale verabreichung von aminoglykosiden
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
JP4792457B2 (ja) 2004-03-26 2011-10-12 ユニヴァーシタ’デグリ ステュディ ディ パルマ 高度に呼吸に適したインスリンのマイクロ粒子
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
WO2009020434A1 (en) * 2007-08-07 2009-02-12 Nanomaterials Technology Pte Ltd A process for making micro-sized protein particles
EP2222639A1 (de) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryle als pde4-inhibitoren zur behandlung von lungen- und herz-kreislauf-erkrankungen
MX2010007430A (es) 2008-01-11 2010-12-21 Albany Molecular Res Inc Piridoindoles (1-azinona)-sustituidos como antagonistas de la hormona de concentracion melanina humana.
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
EP2910571B1 (de) 2008-03-18 2016-10-05 Novo Nordisk A/S Proteasestabilisierte, acylierte insulinanaloga
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
KR20150116466A (ko) 2009-01-26 2015-10-15 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
WO2015052088A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
US9993488B2 (en) 2014-02-20 2018-06-12 Otitopic Inc. Dry powder formulations for inhalation
EP4218734A1 (de) 2014-07-31 2023-08-02 Vectura Inc. Trockenpulverformulierungen zur inhalation
MX2019006463A (es) 2016-12-16 2019-08-14 Novo Nordisk As Composiciones farmaceuticas que contienen insulina.
US11866427B2 (en) 2018-03-20 2024-01-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
IT201800006336A1 (it) * 2018-06-14 2019-12-14 Glutatione ridotto in forma solida amorfa altamente solubile e processo per ottenerlo
CA3111275A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
CN113508111A (zh) 2018-12-31 2021-10-15 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227855B (de) * 1960-07-12 1966-11-03 Ichthyol Ges Verfahren zur Herstellung von Enzymkoerpern fuer die Durchfuehrung enzymatischer Reaktionen
DE1517787A1 (de) * 1965-12-06 1970-01-29 Takeda Chemical Industries Ltd Enzympraeparat und Verfahren zu seiner Herstellung
CS180896B1 (en) * 1975-07-22 1978-02-28 Pavel Veber Process for treatment of agents for releasing cells from fabrics and surface of cultivation vessels
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE268605T1 (de) * 1994-03-04 2004-06-15 Genentech Inc Pharmazeutische akzeptabel dnase zusammensetzung
PL179443B1 (pl) * 1994-03-07 2000-09-29 Inhale Therapeutic Syst Kompozycja insuliny, sposób wytwarzania kompozycji insuliny i sposób wytwarzania dawki insuliny w postaci aerozolu PL PL PL PL

Also Published As

Publication number Publication date
ES2303378T3 (es) 2008-08-01
EA200100088A1 (ru) 2001-06-25
DK1091729T3 (da) 2008-07-21
GB9814172D0 (en) 1998-08-26
BR9911697A (pt) 2001-03-20
CA2336376A1 (en) 2000-01-06
CA2336376C (en) 2008-11-25
CN1317958A (zh) 2001-10-17
CN1198582C (zh) 2005-04-27
EP1091729B1 (de) 2008-04-02
EP1091729A1 (de) 2001-04-18
AU4523399A (en) 2000-01-17
IL140306A0 (en) 2002-02-10
DE69938452D1 (de) 2008-05-15
DE69938452T2 (de) 2009-05-07
WO2000000176A1 (en) 2000-01-06
JP2002519315A (ja) 2002-07-02
AU752563B2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
ATE390915T1 (de) Sprühgetrocknete insulin-mikropartikel zur inhalation
NZ515392A (en) Respiratory syncytial virus replication inhibitors
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
MY124329A (en) Active substance concentrate with formoterol, suitable for storage.
GB0105772D0 (en) Use
BR9914507A (pt) Concentrado de substância ativa com formoterol, adequado para armazenagem
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
AU2002316771A1 (en) Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
WO2002015876A3 (en) Amorphous carrier materials for drug delivery
TW200501935A (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
ATE271852T1 (de) Verbesserte inhalationspräparate
DE60111622D1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
EP1297838A4 (de) Pralmorelin-haltige nasentropfen-präparate
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
DE60202299D1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
DE60022047D1 (de) Antivirale therapie
MX9102702A (es) Administracion de alfa interferon mediante inhalacion oral para tratar asma y enfermedades pulmonarias proliferativas, no malignas.
RU2000108989A (ru) Способ профилактики и лечения респираторных болезней телят
RU99122488A (ru) Способ лечения рака эндометрия
RU97116821A (ru) Способ лечения респираторных заболеваний
RU93002216A (ru) Ингалятор

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1091729

Country of ref document: EP

REN Ceased due to non-payment of the annual fee